| Literature DB >> 31875548 |
Deepak Parashar1, Anjali Geethadevi1, Miriam Ragle Aure2, Jyotsna Mishra3, Jasmine George1, Changliang Chen1, Manoj K Mishra4, Andliena Tahiri5, Wei Zhao6, Bindu Nair1, Yiling Lu6, Lingegowda S Mangala7, Cristian Rodriguez-Aguayo8, Gabriel Lopez-Berestein8, Amadou K S Camara3, Mingyu Liang4, Janet S Rader9, Ramani Ramchandran10, Ming You11, Anil K Sood7, Vessela N Kristensen12, Gordon B Mills6, Sunila Pradeep13, Pradeep Chaluvally-Raghavan14.
Abstract
Genomic amplification of 3q26.2 locus leads to the increased expression of microRNA 551b-3p (miR551b-3p) in triple-negative breast cancer (TNBC). Our results demonstrate that miR551b-3p translocates to the nucleus with the aid of importin-8 (IPO8) and activates STAT3 transcription. As a consequence, miR551b upregulates the expression of oncostatin M receptor (OSMR) and interleukin-31 receptor-α (IL-31RA) as well as their ligands OSM and IL-31 through STAT3 transcription. We defined this set of genes induced by miR551b-3p as the "oncostatin signaling module," which provides oncogenic addictions in cancer cells. Notably, OSM is highly expressed in TNBC, and the elevated expression of OSM associates with poor outcome in estrogen-receptor-negative breast cancer patients. Conversely, targeting miR551b with anti-miR551b-3p reduced the expression of the OSM signaling module and reduced tumor growth, as well as migration and invasion of breast cancer cells.Entities:
Keywords: IPO8; OSMR; RNAi; STAT3; miR551b; miRNA-therapy; oncostatin
Mesh：
Substances：
Year: 2019 PMID： 31875548 PMCID： PMC7380555 DOI： 10.1016/j.celrep.2019.11.085
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423